Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors

Abstract PD‐1/PD‐L1 (programmed cell death‐1 and programmed death‐ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti‐PD‐1/PD‐L1 therapy. A comprehensive search was conducted in electronic databases to i...

Full description

Bibliographic Details
Main Authors: Zhiyang Li, Xin Wu, Yanjie Zhao, Yinan Xiao, Yunuo Zhao, Ting Zhang, Hui Li, Fushen Sha, Yating Wang, Lei Deng, Xuelei Ma
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:MedComm
Subjects:
atezolizumab
lung cancer
neoadjuavant therapy
PD‐1/PD‐L1 inhibitors
triple‐negative breast cancer
Online Access:https://doi.org/10.1002/mco2.61

Internet

https://doi.org/10.1002/mco2.61

Similar Items